Full Press Release Details
Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress
- Four Products Currently Under Review with the FDA -
- Expecting Multiple Product Launches in Second Half of 2019 -
- Company to Host Conference Call and Webcast today at 4:30 p.m. ET (3:30 p.m. CT) -
PARK, Ill., May. 7, 2019 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company
focused on developing and commercializing innovative drug products, reported financial results for the first quarter ended March
31, 2019 and provided a business update.
is off to a great start as we began the year with a very productive first quarter. We added three late-stage product candidates
to our pipeline, executed a partnership with Bausch Health for the commercialization of EM-100, and submitted the NDA for DS-200,"
said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. "We remain on track to reach our goal of becoming
a commercial revenue company in 2019 as we expect multiple product launches in the second half of this year. We have begun preparing
for the launch of ET-202, our ready-to-use injectable formulation of phenylephrine which, if approved, could be the first and
only FDA-approved ready-to-use phenylephrine product in the market."
Quarter Business Milestones:
| Acquired rights to ET-104 . In January, Eton acquired marketing rights to ET-104, a patent-pending oral liquid product candidate for treatment of a neurological condition. A clinical study of ET-104 is expected to initiate in the second quarter of 2019. If successful, Eton anticipates an NDA submission before year end 2019. | ||
| Acquired rights to two late-stage hospital ready-to-use products . In February, Eton acquired marketing rights from Sintetica SA for ET-202 and ET-203. Both products are innovative, ready-to-use injectable products administered in the hospital setting. The NDA for ET-202 has been filed with the FDA, and the NDA for ET-203 is expected to be submitted by the third quarter of 2019. | ||
| Established commercialization partnership with Bausch Health for EM-100 . In February, Eton announced an agreement with Bausch Health for the commercialization of EM-100, its innovative ophthalmic solution currently under review with the FDA. If approved, EM-100 is expected to be the first and only preservative-free product that is FDA-approved for the treatment of allergic conjunctivitis. |
| Product | Dosage Form | Expecting Filing Year | ||
| ET-202 | Injectable | Submitted | ||
| DS-300 | Injectable | Submitted | ||
| DS-200 | Injectable | Submitted | ||
| EM-100 | Ophthalmic | Submitted | ||
| ET-203 | Injectable | 2019 | ||
| ET-103 | Oral Liquid | 2019 | ||
| ET-104 | Oral Liquid | 2019 | ||
| DS-200 | Injectable | 2020 | ||
| ET-101 | Oral Liquid | 2020 | ||
| ET-102 | Oral Liquid | 2020 | ||
| ET-201 | Injectable | 2020 | ||
| CT-100 | Injectable | TBD |
now has twelve products under various stages of development. Four of these products have been submitted to the FDA, which the
company believes could be approved and launched within the next twelve months, including:
During the first quarter, ET-202, Eton's ready-to-use injectable formulation of phenylephrine for increasing blood pressure
in adults with clinically significant hypotension resulting primarily from vasodilation in such settings as septic shock or anesthesia,
was assigned a Prescription Drug User Fee Act (PDUFA) date of October 21, 2019.
FDA-approved phenylephrine is only available in highly concentrated doses that require dilution prior to administration. As a
result, phenylephrine is believed to be one of the most frequently compounded products in the hospital setting. Compounded drugs
do not have to undergo FDA premarket review for safety, effectiveness and quality. Due to this lower regulatory standard, compounded
drugs are at higher risk for medication error and patient safety issues. In 2018, the FDA released a 2018 Compounding Priorities
Plan restricting the use of compounded drugs when an FDA-approved drug is available.
ET-202's approval, hospitals will no longer need to rely on compounders for ready-to-use phenylephrine. In addition, ET-202
will align with best practice recommendations from the American Society of Hospital Pharmacists (ASHP), which recommends that
hospitals use standardized concentrations, use commercially available products instead of compounded products, and dispense medications
in the most ready-to-administer form available.
believes ET-202 could provide significant benefits to hospitals over the current compounded or manually diluted products, including:
reduced risk of dilution or compounding errors, significantly reduced waste due to improved shelf-life, reduced labor costs, and
improved sterility assurance.
According to IQVIA data, more than 7 million vials of phenylephrine concentrate were sold last year
and the entire vasopressor market is estimated to be more than 25 million vials and $650 million in sales annually.
has begun preparing for commercial launch of ET-202 and, if approved on its PDUFA date, Eton plans to launch the product in the
fourth quarter of 2019.
DS-300 is an injectable nutrition product administered in the hospital setting. Its NDA was submitted under a Rolling Review and
has not been assigned a PDUFA date.
DS-200. DS-200 is an injectable nutrition product administered in the hospital setting.
Its NDA was submitted under a Rolling Review and has not been assigned a PDUFA date.
EM-100 is Eton's preservative-free ophthalmic solution for the treatment of allergic conjunctivitis. The product is currently
under review with the FDA and has been assigned a target action date of May 2019 or July 2019 depending on whether the FDA chooses
to inspect EM-100's manufacturing site. Bausch Health is responsible for all commercialization activities for the product.
Quarter 2019 Financial Results
Position: As of March 31, 2019, Eton reported cash and cash equivalents of $19.6 million compared to $26.7 million at December
Revenue was $0.5 million in the first quarter of 2019 which resulted from the upfront payment associated with Eton's
EM-100 asset sale to Bausch Health in February. Eton had no revenue in the prior year period.
and Development (R&D) Expenses: R&D expenses were $6.5 million for the first quarter of 2019 compared to $1.3 million
for the same period in 2018. The increase was primarily driven by $3.4 million of licensing payments to acquire the rights to
ET-104, ET-202, and ET-203. In addition, Eton recognized a $1.5 million milestone expense associated with its DS-200 NDA submission
in March and incurred increased headcount and operating costs related to the start-up of its research and development laboratory.
& Administrative (G&A) Expenses: G&A expenses were $1.6 million for the first quarter of 2019, compared to $1.7
million for the same period in 2018. The decrease was primarily driven by a decline in stock-based compensation partially offset
by increased employee compensation costs for staff additions and public company expenses.
Loss: Eton reported a net loss for the first quarter of 2019 of $7.4 million compared to a net loss of $3.0 million for the
same period of 2018. The increase in the loss was primarily driven by higher R&D expenses for licensing fees and milestone
expenses combined with increased headcount and operating costs related to the start-up of its research and development laboratory,
partially offset by lower stock-based compensation expenses.
Call and Webcast Information:
Pharmaceuticals will host a conference call and webcast today at 4:30 p.m. ET (3:30 p.m. CT). To access the conference call, please
dial 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 2165318. The webcast can be accessed
under "Events & Presentations" in the Investors section of the Company's website at https://etonpharma.com/.
The webcast will be archived and made available for replay on the company's website approximately two hours after the call
and will be available for 30 days.
Eton Pharmaceuticals
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing
the FDA's 505(b)(2) regulatory pathway. Eton is primarily focused on liquid dosage forms including injectables, oral liquids
and ophthalmics. Eton has a diversified pipeline of high-value product candidates in various stages of development and therapeutic
areas, including multiple product candidates currently pending regulatory approval with the FDA.
Forward-Looking Statements
contained in this press release regarding matters that are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability
of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited
to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates,
the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory
filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements
are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking
statements. Words such as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics,
and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs
and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission.
All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes
no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they
Pharmaceuticals, Inc.
Statements of Operations
thousands, except per share amounts)
| For the three months ended March 31, 2019 | For the three months ended March 31, 2018 | |||||||
| Revenues | $ | 500 | $ | - | ||||
| Operating expenses: | ||||||||
| Research and development | 6,465 | 1,274 | ||||||
| General and administrative | 1,589 | 1,690 | ||||||
| Total operating expenses | 8,054 | 2,964 | ||||||
| Loss from operations | (7,554 | ) | (2,964 | ) | ||||
| Other income (expense): | ||||||||
| Interest and other income, net | 144 | 29 | ||||||
| Change in fair value of warrant liability | - | (83 | ) | |||||
| Loss before income tax expense | (7,410 | ) | (3,018 | ) | ||||
| Income tax expense | - | - | ||||||
| Net loss | (7,410 | ) | (3,018 | ) | ||||
| Accrued dividends on redeemable convertible preferred stock | - | (296 | ) | |||||
| Deemed dividends for accretion of redeemable convertible preferred stock issuance costs | - | (410 | ) | |||||
| Net loss attributable to common stockholders | $ | (7,410 | ) | $ | (3,724 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.42 | ) | $ | (1.05 | ) | ||
| Weighted average number of common shares outstanding, basic and diluted | 17,502 | 3,551 |
Pharmaceuticals, Inc.
thousands, except share and per share amounts)
| March 31, 2019 | December 31, 2018 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 19,584 | $ | 26,735 | ||||
| Prepaid expenses and other current assets | 1,943 | 767 | ||||||
| Total current assets | 21,527 | 27,502 | ||||||
| Property and equipment, net | 1,190 | 773 | ||||||
| Operating lease right-of-use assets, net | 252 | - | ||||||
| Other long-term assets, net | 48 | 52 | ||||||
| Total assets | $ | 23,017 | $ | 28,327 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,208 | $ | 1,421 | ||||
| Accrued liabilities | 448 | 603 | ||||||
| Total current liabilities | 3,656 | 2,024 | ||||||
| Operating lease liabilities, net of current portion | 119 | - | ||||||
| Total liabilities | 3,775 | 2,024 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Common stock, $0.001 par value; 50,000,000 shares authorized; 17,627,928 and 17,607,928 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively | 18 | 18 | ||||||
| Additional paid-in capital | 72,502 | 72,153 | ||||||
| Accumulated deficit | (53,278 | ) | (45,868 | ) | ||||
| Total stockholders' equity | 19,242 | 26,303 | ||||||
| Total liabilities and stockholders' equity | $ | 23,017 | $ | 28,327 |
Pharmaceuticals, Inc.
Statements of Cash Flows
| Three months ended March 31, 2019 | Three months ended March 31, 2018 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (7,410 | ) | $ | (3,018 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | 345 | 1,050 | ||||||
| Depreciation and amortization | 55 | 10 | ||||||
| Change in fair value of warrant liability | - | 83 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other assets | (1,187 | ) | (129 | ) | ||||
| Accounts payable | 1,736 | 262 | ||||||
| Accrued liabilities | (306 | ) | (108 | ) | ||||
| Net cash used in operating activities | (6,767 | ) | (1,850 | ) | ||||
| Cash used in investing activities | ||||||||
| Purchases of property and equipment | (388 | ) | (91 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from stock option exercises | 4 | - | ||||||
| Net cash provided by financing activities | 4 | - | ||||||
| Change in cash and cash equivalents | (7,151 | ) | (1,941 | ) | ||||
| Cash and cash equivalents at beginning of period | 26,735 | 13,156 | ||||||
| Cash and cash equivalents at end of period | $ | 19,584 | $ | 11,215 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid for interest | $ | - | $ | - | ||||
| Cash paid for income taxes | $ | - | $ | - | ||||
| Supplemental disclosures of non-cash investing and financing activities: | ||||||||
| Accrued dividends on redeemable convertible preferred stock | $ | - | $ | 296 | ||||
| Deemed dividends for accretion of redeemable convertible preferred stock issuance costs | $ | - | $ | 410 | ||||
| Purchases of equipment included in accounts payable | $ | 51 | $ | - |
Stern Investor Relations, Inc.